Liquidia is actively seeking life science partners to collaborate with and/or license its PRINT® technology to enhance drug design and development activities across a range of therapeutic areas, molecule types, and routes of administration.
PRINT particles can be designed to help partners address specific pharmacological or therapeutic objectives, such as enhancing the route of administration, improving solubility, enhancing stability or extending therapeutic effects. Using our PRINT technology, we are able to engineer, among others, small molecule and biologic particles, single agent drug and combination drug particles and vaccine particles to improve efficacy, safety and convenience for patients.
Please fill out this form if you are interested in working with us. We look forward to hearing from you!